Skip to main content
xMedica

Search

63 studies match these filters. Showing 51–63 of 63 studies

Search results
Registration numberStudyStatusPhaseEnrolmentSites / countriesStart yearLast updatedActions
NCT04852887De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.

Contact Claimed

Nearest site: Wichita, Kansas, United States — 43 km away · 832 sites in total · contact listed

RecruitingPhase 31,670target832 / 42021Apr 23, 2026
NCT06880055Shield Post-Approval Study Protocol

The Shield post-approval study (PAS) is a prospective, longitudinal study supplemented with Real World Evidence (RWE) to evaluate the longitudinal performance of Shield in an average risk population at a second round of testing for individuals between the ages of 45 and 81 at average risk of CRC usi…

Contact Claimed

Nearest site: Hutchinson, Kansas, United States — 36 km away · 69 sites in total

Recruiting3,375target69 / 12025Aug 7, 2026
NCT06319820A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.

Contact Claimed

Nearest site: Wichita, Kansas, United States — 43 km away · 193 sites in total

RecruitingPhase 3641target193 / 202024Aug 28, 2026
NCT02523014Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the g…

Contact Claimed

Nearest site: Kingman, Kansas, United States — 28 km away · 783 sites in total

RecruitingPhase 2124target783 / 12015Sep 2, 2026
NCT06122077Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening

The PROACT LUNG study is a prospective multi-center observational study to validate a blood-based test for the early detection of lung cancer by collecting blood samples from high-risk participants who will undergo a routine, standard-of-care screening Low-Dose Computed Tomography (LDCT).

Contact Claimed

Nearest site: Wichita, Kansas, United States — 43 km away · 36 sites in total · contact listed

Recruiting20,000target36 / 12023Aug 5, 2025
NCT06567743Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer.

Contact Claimed

Nearest site: Wichita, Kansas, United States — 43 km away · 80 sites in total · contact listed

RecruitingPhase 2325target80 / 22024Sep 3, 2026
NCT07190300TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

The purpose of the study is to evaluate the safety, tolerability, and efficacy of the two different treatment combinations of tulmimetostat in participants with de novo or recurrent Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).

Contact Claimed

Nearest site: Wichita, Kansas, United States — 43 km away · 31 sites in total · contact listed

RecruitingPhase 1 / Phase 2181target31 / 142026Jun 23, 2026
NCT07764978Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of standard induction regimens (IsaVRd and DRd) followed by AZD0120 versus standard induction regimens followed by continuous therapy (IsaRd and DRd) in participants with newly diagnos…

Contact Claimed

Nearest site: Wichita, Kansas, United States — 43 km away · 124 sites in total

RecruitingPhase 3750target124 / 152026Aug 14, 2026
NCT05491525Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC

The purpose of this study is to evaluate the safety, efficacy, and PK of Vibegron in pediatric participants with NDO who are regularly using CIC

Contact Claimed

Nearest site: Wichita, Kansas, United States — 43 km away · 38 sites in total · contact listed

RecruitingPhase 2 / Phase 371target38 / 162022Jun 15, 2026
NCT07296484Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

CAPTAIN-T2D will take place in two parts. Part 1 (Screening) will evaluate patients with type 2 diabetes and elevated cortisol risk factors for trial eligibility and the presence of elevated cortisol. Participants deemed eligible from Part 1 will be randomized to either clofutriben or placebo in the…

Contact Claimed

Nearest site: Wichita, Kansas, United States — 43 km away · 61 sites in total · contact listed

RecruitingPhase 21,500target61 / 12025Sep 9, 2026
NCT05862272A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis

The purpose of this clinical trial to characterize changes in bone mineral density during continuous treatment with relugolix combination tablet for up to 48 months (4 years) and 1 year of post-treatment follow-up in premenopausal women with heavy menstrual bleeding associated with uterine leiomyoma…

Contact Claimed

Nearest site: Wichita, Kansas, United States — 43 km away · 120 sites in total

RecruitingPhase 31,000target120 / 12023Aug 6, 2025
NCT05336240PCOM2 - The Physician Communication Intervention, Version 2.0

Poor quality of primary care providers' vaccine recommendations lead to low adolescent human papillomavirus vaccination rates and hundreds of thousands of adolescents unnecessarily at risk for HPV-associated cancers and diseases. Though a previous provider communication intervention, called PCOM, wa…

Contact Claimed

Nearest site: Wichita, Kansas, United States — 43 km away · 2 sites in total · contact listed

RecruitingNot applicable120target2 / 12023Aug 26, 2024
NCT07546929HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes

Blood sugar levels are controlled by insulin, a hormone made by cells in the pancreas. After a meal, carbohydrates are broken down into glucose which is absorbed from the intestine into the blood leading to a rise in glucose (blood sugar) which triggers the secretion of insulin. Insulin binds to cel…

Contact Claimed

Nearest site: El Dorado, Kansas, United States — 85 km away · 25 sites in total · contact listed

RecruitingPhase 2300target25 / 12023Apr 23, 2026

Filters

Clear all filters